Butler, C. C., Dorward, J., Ly-Mee Yu, Gbinigie, O., Hayward, G., Saville, B. R., Van Hecke, O., Berry, N., Detry, M., Saunders, C., Fitzgerald, M., Harris, V., Patel, M. G., de Lusignan, S., Ogburn, E., Evans, P. H., Thomas, N. P., Hobbs, F. R., & PRINCIPLE Trial Collaborative Group. (2021). Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, 397(10279), 1063-1074. https://doi.org/10.1016/S0140-6736(21)00461-X

BUTLER, Christopher C., DORWARD, Jienchi, LY-MEE YU, GBINIGIE, Oghenekome, HAYWARD, Gail, SAVILLE, Benjamin R., VAN HECKE, Oliver, BERRY, Nick, DETRY, Michelle, SAUNDERS, Christina, FITZGERALD, Mark, HARRIS, Victoria, PATEL, Mahendra G., DE LUSIGNAN, Simon, OGBURN, Emma, EVANS, Philip H., THOMAS, Nicholas PB, HOBBS, FD Richard und PRINCIPLE TRIAL COLLABORATIVE GROUP, 2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 20 März 2021. Vol. 397, no. 10279, p. 1063-1074. DOI 10.1016/S0140-6736(21)00461-X.

Butler, C. C., J. Dorward, Ly-Mee Yu, O. Gbinigie, G. Hayward, B. R. Saville, O. Van Hecke, N. Berry, M. Detry, C. Saunders, M. Fitzgerald, V. Harris, M. G. Patel, S. de Lusignan, E. Ogburn, P. H. Evans, N. P. Thomas, F. R. Hobbs, und PRINCIPLE Trial Collaborative Group. „Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial.“. Lancet, Bd. 397, Nr. 10279, März 2021, S. 1063-74, https://doi.org/10.1016/S0140-6736(21)00461-X.

Butler, Christopher C./Dorward, Jienchi/Ly-Mee Yu/Gbinigie, Oghenekome/Hayward, Gail/Saville, Benjamin R. u. a.: Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial., Lancet 2021, 1063-1074.

Butler, C.C., Dorward, J., Ly-Mee Yu, Gbinigie, O., Hayward, G., Saville, B.R., Van Hecke, O., Berry, N., Detry, M., Saunders, C., Fitzgerald, M., Harris, V., Patel, M.G., de Lusignan, S., Ogburn, E., Evans, P.H., Thomas, N.P., Hobbs, F.R. und PRINCIPLE Trial Collaborative Group. (2021), „Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.“, Lancet, Vol. 397 No. 10279, S. 1063-1074.